Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Next Previous
Trial Profile

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XMT 1522 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Mersana Therapeutics

    • Most Recent Events

    • 23 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 17 Sep 2018 According to the Mersana Therapeutics media release, protocol amendment of the study includes, increased monitoring as well as the exclusion of patients with advanced hepatic impairment. Also, alternative dosing regimens will be evaluated that is the trial will begin with a once-every-four-week dose regimen. (company may evaluate additional regimens as well).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top